Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 6;21:21. doi: 10.1186/s12935-020-01723-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 3 — The anti-tumor effect of ferrichrome was greater than that of 5-FU or cisplatin. An SRB assay for SW620 revealed that the tumor-suppressive effect of ferrichrome was superior to that of 5-FU and cisplatin (a). Ferrichrome (0.5 mg/kg) and 5-FU (0.5 mg/kg) significantly suppressed the tumor growth in comparison to the control, and the tumor volume of the ferrichrome treated group also significantly decreased in comparison to the 5-FU treated group (b). An SRB assay showed that the anti-tumor effect of 0.2 µg/mL of ferrichrome was equal or greater than that of 0.2 µg/mL of 5-FU or cisplatin, and the combination of ferrichrome and 5-FU greatly reduced the density of SW620 cells compared to treatment with 5-FU alone (c, d). *p < 0.05 by a two-way ANOVA followed by Ryan’s post hoc test. The error bars show the standard deviation (S.D.)